In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Par Pharmaceutical Companies Inc.

http://www.parpharm.com

Latest From Par Pharmaceutical Companies Inc.

FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle

Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.

M & A Commercial

Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition

Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.

Deals M & A

Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached

Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.

Deals M & A

Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge

The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.

Generic Drugs Neurology
See All

Company Information

  • Other Names / Subsidiaries
    • Anchen Pharmaceuticals, Inc.
    • Edict Pharmaceuticals Private Limited
    • JHP Pharmaceuticals, LLC
    • Strativa Pharmaceuticals
    • TPG Capital LP
UsernamePublicRestriction

Register